Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2024 Financial Results
1. Sales for Q4 2024 reached $873 million, a 6% increase from Q4 2023. 2. Pharmaceutical sales grew 10% in constant currency, driven by strong year-end dynamics. 3. Non-GAAP EPS for Q4 2024 increased by 13% to $4.10, despite FX headwinds. 4. 2025 sales growth guidance forecasts 2.5% to 5.0% reported growth in constant currency. 5. Full-year 2024 sales were flat at $2.958 billion, as currency impacts mitigated growth.